CN112522392B - Biomarker for diabetes complicated with coronary heart disease - Google Patents
Biomarker for diabetes complicated with coronary heart disease Download PDFInfo
- Publication number
- CN112522392B CN112522392B CN202011594859.1A CN202011594859A CN112522392B CN 112522392 B CN112522392 B CN 112522392B CN 202011594859 A CN202011594859 A CN 202011594859A CN 112522392 B CN112522392 B CN 112522392B
- Authority
- CN
- China
- Prior art keywords
- heart disease
- coronary heart
- diabetes
- serum
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a biomarker for diabetes complicated with coronary heart disease, and belongs to the technical field of biological medicines. According to the invention, compared with the serum of a healthy human body, the expression level of the gene AC021188.4 in the serum of a patient with diabetes and coronary heart disease is obviously reduced by extracting RNA, and the expression level of AC021188.4 has no obvious change in the serum of the patient with simple coronary heart disease and the serum of the patient with simple diabetes, so that AC021188.4 can be used as a gene marker for diagnosing the patient with diabetes and coronary heart disease.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to a biomarker for diabetes complicated with coronary heart disease.
Background
With the aging population becoming more severe, the incidence of coronary heart disease and diabetes is increasing year by year. Relevant research data show that the incidence of coronary heart disease of diabetic patients is 2-4 times of that of normal people. Compared with the patients with simple coronary heart disease, the patients with diabetes complicated with coronary heart disease have more diffuse and serious coronary artery pathological changes. It can be seen that diabetes combined with coronary heart disease has become a major disease that seriously threatens human life and health. Therefore, the early diagnosis of the diabetes and coronary heart disease is beneficial to the early treatment of the diabetes and coronary heart disease, and the cure rate of patients is improved.
lncRNA is a non-coding RNA with more than 200 nucleotides, and has wide regulation and control functions in various life activities of a human body. Research in recent years shows that the differential expression of lncRNA is closely related to the occurrence and development of human diseases. At present, no report related to lncRNA and diabetes-associated coronary heart disease exists, so that research on lncRNA differential expression in blood of patients with diabetes-associated coronary heart disease provides a new direction for diagnosing and treating diabetes-associated coronary heart disease.
Disclosure of Invention
The invention aims to provide a new direction for diagnosing and treating a diabetic coronary heart disease patient by using differential lncRNA in blood of the diabetic coronary heart disease patient.
In order to achieve the purpose, the invention provides the following technical scheme:
the invention provides a marker for diagnosing diabetes combined with coronary heart disease, wherein the marker is gene AC021188.4, the transcript sequence of the gene AC021188.4 is ENST00000421534.1, and ENST00000421534.1 is shown as SEQ ID No. 1.
Secondly, the invention provides application of a reagent for detecting the expression level of the gene AC021188.4 in preparing a product for pre-diagnosing diabetes complicated with coronary heart disease.
Preferably, the product is a gene chip, a kit or a biological agent.
Preferably, a primer specific to AC021188.4 is included in the reagent, and the sequence of the primer is shown as SEQ ID NO.2 and SEQ ID NO. 3.
The invention also provides a diabetes combined coronary heart disease pre-diagnosis detection kit, which comprises a specific primer for detecting the expression quantity of AC021188.4, wherein the sequence of the primer is shown as SEQ ID NO.2 and SEQ ID NO. 3.
Fourthly, the invention provides application of a reagent for detecting the expression level of the gene AC021188.4 in preparation of a product for prognosis evaluation of diabetes mellitus with coronary heart disease.
Preferably, the product is a gene chip, a kit or a biological agent.
Preferably, a primer specific to AC021188.4 is included in the reagent, and the sequence of the primer is shown as SEQ ID NO.2 and SEQ ID NO. 3.
The invention also provides a diabetes-associated coronary heart disease prognosis evaluation detection kit, which comprises a specific primer for detecting the expression quantity of AC021188.4, wherein the sequences of the primer are shown as SEQ ID NO.2 and SEQ ID NO. 3.
The invention has the beneficial effects that:
the gene AC021188.4 is found to be low expressed in patients with diabetes complicated with coronary heart disease for the first time, the expression of the gene AC021188.4 has no obvious difference between the patients with simple coronary heart disease and the patients with simple diabetes, and the gene AC021188.4 has excellent specificity and sensitivity as a marker of the diabetes complicated with coronary heart disease, so the gene AC021188.4 can be used for preparing a pre-diagnosis kit of the diabetes complicated with coronary heart disease and a prognosis diagnosis kit of the diabetes complicated with coronary heart disease.
Drawings
FIG. 1 expression differences of AC021188.4 in healthy human serum (group A), diabetic combined coronary serum (group B), simple coronary serum (group C) and simple diabetic serum (group D).
FIG. 2 ROC curves of AC021188.4 between healthy human serum (group A) and serum from diabetic patients combined with coronary disease (group B).
Detailed Description
In order to clearly illustrate the technical features of the present solution, the present solution is explained below by way of specific embodiments.
Example 1
Extraction of serum RNA
(1) Collecting 30 healthy human blood (set as group a), 22 diabetic combined coronary blood (set as group B) and 25 simple coronary blood (set as group C) and 20 simple diabetic blood (set as group D);
(2) placing the blood plasma of each group in a centrifuge, centrifuging for 15min at 3000rpm/min, and taking the supernatant to obtain serum;
(3) respectively taking 250ul of serum from each group, placing the serum into a centrifuge tube, adding 750ul of Invitrogen TRIzol reagent, blowing, uniformly mixing, and standing at room temperature for 5 min;
(4) adding 200ul chloroform, shaking and mixing uniformly, and standing at room temperature for 15 min;
(5) placing the centrifuge tube in a low-temperature centrifuge, and centrifuging at 4 ℃ and 12000rpm/min for 15 min;
(6) sucking the supernatant into a new centrifugal tube, adding isopropanol with the same volume, uniformly mixing, and standing on ice for 10 min;
(7) placing the centrifuge tube in a low-temperature centrifuge, and centrifuging at 4 ℃ and 12000rpm/min for 15 min;
(8) discarding the supernatant, adding 1ml of 75% ethanol prepared by DEPC water into the precipitate, and shaking the centrifugal tube to suspend the precipitate in the 75% ethanol;
(9) placing the centrifuge tube in a low temperature centrifuge, centrifuging at 4 deg.C 7000rpm/min for 5min, discarding supernatant, placing in a superclean bench, drying for 8min, and adding 30ul DEPC water for dissolving;
(10) the purity and concentration of the RNA were determined for subsequent experiments.
Example 2
Preparation of cDNA for each group of sera
(1) Removal of genomic DNA
The reaction system is as follows:
| reagent | Amount of the composition used |
| 5×gDNA Eraser Buffer | 2.0 μl |
| gDNA Eraser | 1μl |
| Total RNA | 1μg |
| RNase Free dH2O | up to 10 μl |
The reaction conditions were as follows: 42 ℃ for 2 minutes, 4 ℃.
(2) Reverse transcription reaction
The reaction system is as follows:
| reagent | Amount of the composition used |
| Reaction solution of step (1) | 10μl |
| PrimeScript RT Enzyme Mix I | 1.0μl |
| RT Primer Mix | 1.0 μl |
| 5×PrimeScript Buffer 2 | 4.0 μl |
| RNase Free dH2O | 4.0 μl |
| Total | 20 μl |
The reaction conditions were as follows: 15min at 37 ℃; 5s at 85 ℃; 4 ℃ is prepared.
Example 3
Detection of differential expression of AC021188.4 in each group
(1) Specific primers of AC021188.4 were designed, and the primer sequences were as follows:
AC021188.4 upstream primer: 5'-CACATCGAGGCTCTAGTGACC-3'
AC021188.4 downstream primer: 5'-GCTTGCCAGCACGATTTACAA-3'
GAPDH upstream primer: 5'-CCCATCACCATCTTCCAGGAG-3'
GAPDH downstream primer: 5'-TTCTCCATGGTGGTGAAGACG-3'
(2) Performing fluorescent quantitative PCR reaction:
| reagent | Amount of the composition used |
| SYBR Green Premix Ex Taq（2×） | 10μl |
| Upstream primer | 0.4μl |
| Downstream primer | 0.4μl |
| cDNA template | 2μl |
| Sterile water | 7.2μl |
| Total | 20μl |
Reaction conditions are as follows: 30s at 95 ℃; 5s at 95 ℃, 35s at 60 ℃ and 40 cycles; 45s at 70 ℃.
(3) Use 2-△△CtThe method calculates the differential expression level of AC021188.4 in each group.
As shown in FIG. 1, it can be seen from the results that the relative expression level of AC021188.4 in group B (diabetic patients with coronary heart disease serum) was 0.439. + -. 0.048, the relative expression level of AC021188.4 in group C (simple coronary heart disease serum) was 0.914. + -. 0.030, and the relative expression level of AC021188.4 in group D (simple diabetic patients serum) was 0.983. + -. 0.041.
From the results, the relative expression level of AC021188.4 in the serum of the patients with diabetes and coronary heart disease is obviously lower than that of the serum of healthy people, and the difference has statistical significance; the relative expression level of AC021188.4 in the serum of the coronary heart disease patient and the diabetes patient is not obviously different from the expression level of AC021188.4 in the serum of a healthy human body.
The ROC curve was plotted based on the data of groups a and B, and as a result, as shown in fig. 2, it can be seen that the AUC value of the ROC curve is 0.9621 (std. error is 0.02232,95% confidence interval 0.9184-1.006, P value < 0.0001), indicating that AC021188.4 has excellent specificity and sensitivity as a marker for diabetes combined with coronary heart disease.
In conclusion, the AC021188.4 is low in expression in patients with diabetes complicated with coronary heart disease, but has no significant difference in expression in patients with simple coronary heart disease and patients with simple diabetes, and the AC021188.4 has excellent specificity and sensitivity as a marker of the diabetes complicated with coronary heart disease, so that the AC021188.4 can be used for preparing a pre-diagnosis kit and a prognosis kit for the diabetes complicated with coronary heart disease.
The technical features of the present invention which are not described in the above embodiments may be implemented by or using the prior art, and are not described herein again, of course, the above description is not intended to limit the present invention, and the present invention is not limited to the above examples, and variations, modifications, additions or substitutions which may be made by those skilled in the art within the spirit and scope of the present invention should also fall within the protection scope of the present invention.
Sequence listing
<110> Shandong university's Qilu hospital (Qingdao)
<120> biomarker for diabetes complicated with coronary heart disease
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 740
<212> DNA
<213> Human source (Human)
<400> 1
ggcacatcga ggctctagtg accgcattat gaattagtcc tttccttttc tcctcatgtg 60
attgcagcga gcgctcgtct tgtttgtaaa tcgtgctggc aagccccgtt ttaaccaact 120
acgaatttca tttcggaatg aaaaaggaga cgcactttcg gacagggcag cggttgccgc 180
cggtccttcc tctgagctac cggtccctag aaggaagacc tgccttcgac cgatctggaa 240
atgagtccca gctgcaagcc cagggcggcg gaagccccac gggccgagcc gaagaaagac 300
gaggcggggg acggggagcg tagtgccgcg tgccgggacc cacaacccct ttcccctggg 360
cgctcttccc cgagcggaca ggaaaaagct ctcctttgcc gctgcccatc ccccagggcc 420
caagcgatgc ttcctaaccg cgtggacgca gcttgatggg ggagaaagag ctctgggagc 480
agggcttaga gcctcgtctc gcctcctgcc aactcggtcc ggcaaggttc cgaacctccc 540
tgagcctcag cttcctaatc tggcaaacat gacgacaaaa gtccttctct tttaaggttt 600
gcccacagcc cagctgcatc tgtgaacatg aatgctactt ctacagaaac agagtggaat 660
ctccgaaata cctttgagac cctttcgtgt caggtgggtg ggccacagcc tgatcatgga 720
ataaaagtca gccttaagga 740
<210> 2
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
cacatcgagg ctctagtgac c 21
<210> 3
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
gcttgccagc acgatttaca a 21
<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
cccatcacca tcttccagga g 21
<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ttctccatgg tggtgaagac g 21
Claims (3)
1. The application of the reagent for detecting the expression quantity of the gene AC021188.4 in preparing the product for pre-diagnosing diabetes complicated with coronary heart disease is characterized in that the sequence of the transcript of the gene AC021188.4 is shown as SEQ ID No. 1.
2. The use of claim 1, wherein the product is a gene chip or a kit.
3. The use according to claim 1, wherein a primer specific to AC021188.4 is included in the reagent, and the sequence of the primer is shown in SEQ ID No.2 and SEQ ID No. 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011594859.1A CN112522392B (en) | 2020-12-29 | 2020-12-29 | Biomarker for diabetes complicated with coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011594859.1A CN112522392B (en) | 2020-12-29 | 2020-12-29 | Biomarker for diabetes complicated with coronary heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112522392A CN112522392A (en) | 2021-03-19 |
| CN112522392B true CN112522392B (en) | 2021-08-03 |
Family
ID=74977361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011594859.1A Active CN112522392B (en) | 2020-12-29 | 2020-12-29 | Biomarker for diabetes complicated with coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112522392B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114058693A (en) * | 2021-11-22 | 2022-02-18 | 中国人民解放军总医院第二医学中心 | Coronary heart disease marker PRKAB2 and application thereof |
| CN113981073A (en) * | 2021-12-02 | 2022-01-28 | 山东中医药大学第二附属医院 | Diagnosis target for diabetes combined with asymptomatic myocardial ischemia |
| CN114469983B (en) * | 2022-02-15 | 2022-12-23 | 山东大学齐鲁医院(青岛) | Medicine for treating type 2 diabetes combined with coronary heart disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107014942A (en) * | 2017-05-05 | 2017-08-04 | 北京骐骥生物技术有限公司 | The method that diabetes coronary disease is predicted using lipid biomarkers |
| CN110331197A (en) * | 2019-01-23 | 2019-10-15 | 蔡耿明 | Application of the lncRNA in the product of preparation prediction Head and neck squamous cell carcinoma prognosis |
-
2020
- 2020-12-29 CN CN202011594859.1A patent/CN112522392B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107014942A (en) * | 2017-05-05 | 2017-08-04 | 北京骐骥生物技术有限公司 | The method that diabetes coronary disease is predicted using lipid biomarkers |
| CN110331197A (en) * | 2019-01-23 | 2019-10-15 | 蔡耿明 | Application of the lncRNA in the product of preparation prediction Head and neck squamous cell carcinoma prognosis |
Non-Patent Citations (2)
| Title |
|---|
| AC021188.4;anonymity;《ensembl数据库》;20200131;全文 * |
| anonymity.AC021188.4.《ensembl数据库》.2020, * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112522392A (en) | 2021-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112522392B (en) | Biomarker for diabetes complicated with coronary heart disease | |
| CN110616229A (en) | Fusion gene of FGFR1 translocation blood disease and detection primer and application thereof | |
| CN112011620B (en) | Application of circ-SLC38A1 as target in medicine for inhibiting bladder cancer cells | |
| CN109402262B (en) | PCR detection kit for auxiliary diagnosis of neuroblastoma and method for detecting miR-199a-3p expression level | |
| CN106754918A (en) | Applications of the MicroRNA in the caput femoris necrosis product for preventing or diagnosing glucocorticoid to cause | |
| CN107586842A (en) | A kind of biomarker for clear cell carcinoma of kidney diagnosis and treatment | |
| CN109593852B (en) | Serum miRNA marker related to nasopharyngeal carcinoma auxiliary diagnosis and application thereof | |
| CN108728532B (en) | A kind of Microrna marker and its application | |
| CN110872630A (en) | Long-chain non-coding RNA for glioma diagnosis and application thereof | |
| CN107312851A (en) | Myocardial infarction biomarker miR 1283 | |
| CN106244688A (en) | A kind of mark assessing adenocarcinoma of colon risk | |
| CN106167822A (en) | A kind of long-chain non-coding RNA and application thereof | |
| CN113862349A (en) | Pulmonary fibrosis diagnosis biomarker | |
| CN109402123A (en) | A kind of circular rna hsa-circ-0073004 and its specificity amplification primer and application | |
| CN109536612B (en) | Plasma miRNA marker related to nasopharyngeal carcinoma auxiliary diagnosis and application thereof | |
| CN114292919A (en) | Early Luminal breast cancer risk diagnosis kit | |
| CN109355372B (en) | Application of long-chain non-coding RNA PEV71I-1 in molecular marker for EV71 infection diagnosis | |
| CN116515995B (en) | Serum microRNA marker for detecting hemophagocytic lymphocytohyperplasia and application thereof | |
| CN107254537A (en) | The application of miR 1912 and its target gene in diagnosis and treatment myocardial infarction | |
| CN109913555B (en) | Prostate cancer diagnosis marker, determination method and application thereof | |
| CN114134223B (en) | Blood detection kit for hepatitis C virus-related liver fibrosis | |
| CN117402965A (en) | Colorectal cancer marker, primer, kit and application | |
| CN107502655B (en) | Novel target for inhibiting bladder cancer metastasis and application thereof | |
| CN112813163B (en) | Marker for myocardial injury in gastric cancer chemotherapy | |
| CN113637763B (en) | Use of miRNA biomarker in early diagnosis and treatment of melanoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |